Recent studies showed that inhaled budesonide (200 µg twice per day) reduced the incidence of acute mountain sickness (AMS) after passive ascent to 3700 and 3900 m [1, 2]. These findings raised the possibility that mediators released from the hypoxic lung transmit signals to the brain which contribute to the cerebral processes leading to AMS [3]. Because neither of these studies reflect alpine-style climbing, the present study was performed to test whether inhalation of budesonide at two different doses (200 and 800 µg twice per day) prior to active and rapid ascent (<20 h) to 4559 m prevents AMS in this high-risk setting. Prophylactic inhalation of budesonide does not prevent acute mountain sickness after rapid ascent to high-altitude http://ow.ly/Bc9p30dOz46

中文翻译：

---

快速上升至 4559 m 后吸入布地奈德并不能预防急性高山病

最近的研究表明，在被动上升至 3700 米和 3900 米后，吸入布地奈德（200 µg，每天两次）可降低急性高山病 (AMS) 的发生率 [1, 2]。这些发现提出了一种可能性，即从缺氧肺释放的介质将信号传输到大脑，从而导致 AMS 的大脑过程[3]。由于这些研究均未反映高山式攀登，因此本研究旨在测试在积极和快速上升（<20 小时）至 4559 m 之前吸入两种不同剂量（200 和 800 µg，每天两次）的布地奈德是否可以预防AMS 在这种高风险环境中。快速攀登高海拔后预防性吸入布地奈德并不能预防急性高山病 http://ow.ly/Bc9p30dOz46